Table 1. Baseline characteristics of the subjects in two treatment groups.
| Characteristics | Control group (n = 26) | Liraglutide group (n = 26) | p value |
|---|---|---|---|
| Age (years) | 58.7 ± 11.4 | 59.1 ± 11.8 | 0.90 |
| Male, n (%) | 19 (73%) | 20 (77%) | 0.75 |
| Current smoker, n (%) | 17 (65%) | 15 (58%) | 0.57 |
| Past medical history | |||
| Hypertension, n (%) | 16 (62%) | 17 (65%) | 0.77 |
| Hyperlipidemia, n (%) | 3 (11%) | 4 (15%) | 1.00 |
| Diabetes mellitus, n (%) | 7 (27%) | 5 (19%) | 0.51 |
| Coronary artery disease, n (%) | 20 (77%) | 21 (81%) | 0.73 |
| Atrial fibrillation, n (%) | 5 (19%) | 6 (23%) | 0.73 |
| Heart failure, n (%) | 6 (23%) | 7 (27%) | 0.75 |
| NYHA classes, n (%) | |||
| I | 3 (12%) | 2 (8%) | 1.00 |
| II | 6 (23%) | 7 (27%) | 0.75 |
| III | 10 (38%) | 9 (35%) | 0.77 |
| IV | 7 (27%) | 8 (30%) | 0.76 |
| BMI (kg/m2) | 24.8 ± 3.8 | 25.3 ± 3.4 | 0.62 |
| Systolic blood pressure, (mmHg) | 115 ± 13 | 118 ± 14 | 0.43 |
| Diastolic blood pressure, (mmHg) | 64 ± 15 | 65 ± 13 | 0.79 |
| Hemoglobin (g/dl) | 13.3 ± 1.4 | 13.1 ± 1.3 | 0.59 |
| HbA1c (%) | 5.3 ± 0.4 | 5.4 ± 0.6 | 0.48 |
| Creatinine (mg/dl) | 1.0 ± 0.1 | 1.0 ± 0.2 | 0.99 |
| eGFR (ml/min/1.73 m2) | 83.5 ± 20.3 | 81.4 ± 19.5 | 0.71 |
| Medications, n (%) | |||
| ACEI | 15 (58%) | 16 (62%) | 0.78 |
| β-blocker | 20 (77%) | 21 (81%) | 0.73 |
| Furosemide | 6 (23%) | 8 (31%) | 0.53 |
| Aldosterone antagonist | 11 (42%) | 12 (46%) | 0.78 |
| Digoxin | 4 (15%) | 5 (19%) | 0.71 |
Data are presented as mean value ± standard deviation or number or percentage (%) of patients. ACEI, angiotensin converting enzyme inhibitor; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin.